Harmony Biosciences Holdings, Inc. (HRMY) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Harmony Biosciences published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Harmony Biosciences reports in thousands of dollars; figures here are converted to millions. All of its revenue is net product revenue from one medicine, WAKIX (pitolisant).
• Harmony preannounces quarterly revenue in some quarters (Q2 2026 on July 16, 2026); the report date here is the full results release.

Source: Harmony Biosciences Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

From the earnings release

In its Q3 2026 release, Harmony Biosciences said:

“Based on our results for the first nine months of 2026, WAKIX remains on track to achieve full-year net revenue of $1.0 billion to $1.04 billion.”

“Reiterated full year guidance of $1.0 billion to $1.04 billion.”

Source: Harmony Biosciences Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the HRMY forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net product revenue and diluted EPS, each as first reported in that quarter's results release.

We do not hold a confirmed date for Harmony Biosciences's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Harmony Biosciences has one commercial medicine, WAKIX (pitolisant), a treatment for excessive daytime sleepiness or cataplexy in narcolepsy. WAKIX net revenue was $268.9 million in Q3 2026, up 12% from $239.5 million, and it is all of Harmony's revenue. (Harmony Biosciences Q3 2026 release, Nov 4, 2026)

Harmony Biosciences attributes the growth to patient demand. The estimated average number of patients on WAKIX grew by 400 to 9,350 in Q3 2026, and Harmony said 5 of the last 6 quarters had more than 400 patient additions. It completed an expansion of its field sales, remote sales, field reimbursement and patient outreach teams in Q2. (Harmony Biosciences Q3 2026 release, Nov 4, 2026)

WAKIX is dispensed through three specialty pharmacy customers. Over the first nine months of 2026, CVS Caremark accounted for 39% of gross product revenue, Accredo for 37% and PANTHERx for 24%. (Harmony Biosciences Form 10-Q, Q3 2026, Nov 4, 2026)

Harmony Biosciences estimates that approximately 170,000 people in the U.S. live with narcolepsy, fewer than 50% are diagnosed, and WAKIX brand penetration is approximately 20%. It expects WAKIX exclusivity to last to March 2030, including 6 months of pediatric exclusivity, after settlements with 6 of the 7 generic (ANDA) filers; a ruling in the remaining AET case is expected around February 2027. (Harmony Biosciences Q3 2026 release, Nov 4, 2026)

Harmony Biosciences reports GAAP EPS only. Diluted EPS fell to $0.81 in Q3 2026 from $0.87, on net income of $48.2 million, which Harmony attributed to higher milestone charges and new royalty charges. Research and development expenses of $71.7 million included a $25.0 million milestone charge under the MSN license agreement. (Harmony Biosciences Q3 2026 release, Nov 4, 2026)

Cost of product sold rose to 30% of WAKIX net revenue from 25%, mainly because of new royalties under the Novitium license agreement. The effective tax rate was 18.7%. Diluted weighted average shares were 59,679,319, against 58,717,910 a year earlier. (Harmony Biosciences Q3 2026 release, Nov 4, 2026; Harmony Biosciences Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Harmony Biosciences guides WAKIX net revenue for the full year and reiterated $1.0 billion to $1.04 billion for 2026 with Q3 results. Nine-month net product revenue was $745.6 million. It gives no EPS guidance. (Harmony Biosciences Q3 2026 release, Nov 4, 2026)

Pipeline dates Harmony gives in the release: an FDA decision (PDUFA) on pitolisant GR due April 1, 2027; Phase 1b data for the orexin agonist BP-205 in Q1 2027; and topline Phase 3 data for pitolisant HD in 2027. (Harmony Biosciences Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Harmony Biosciences, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Harmony Biosciences's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning HRMY is on is HRMY a buy or a sell?, what analysts expect next is on the HRMY forecast, and what the company does is on the Harmony Biosciences Holdings, Inc. (HRMY) stock page.

Every number on this page can be traced to a document Harmony Biosciences published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.